Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. (Q54983769)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. (English)

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

Katsuyuki Kiura

1

object named as

Katsuyuki Kiura

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

author name string

Fumio Imamura

2

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Hiroshi Kagamu

3

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Shingo Matsumoto

4

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Toyoaki Hida

5

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Kazuhiko Nakagawa

6

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Miyako Satouchi

7

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Isamu Okamoto

8

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Mitsuhiro Takenoyama

9

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Yasuhito Fujisaka

10

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Takayasu Kurata

11

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Masayuki Ito

12

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Kota Tokushige

13

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Ben Hatano

14

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Makoto Nishio

15

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

publication date

1 April 2018

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Japanese Journal of Clinical Oncology

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

48

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

4

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

367-375

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

21 February 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892855

16 June 2018

Identifiers

10.1093/JJCO/HYY016

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5892855

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54983769&oldid=1896441696"